Cite

    Takeuchi, T., Tanaka, Y., Soen, S., Yamanaka, H., Yoneda, T., Tanaka, S., Nitta, T., Okubo, N., Genant, H., & Heijde, D. v. d. (n.d.). sAT0186 Effects of denosumab, a subcutaneous rankl inhibitor, on the progression of structural damage in japanese patients with rheumatoid arthritis treated with csdmards: results from the 12-month double blind phase 3, desirable study. Annals of the rheumatic diseases, 76, 841–842. http://access.bl.uk/ark:/81055/vdc_100135143035.0x000061